Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering Myeloma

Video

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Romanos Sklavenitis-Pistofidis, MD, postdoctoral fellow, Michele and Steven Kirsch Laboratory, Dana-Farber Cancer Institute, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Researchers used single-cell dissection of bone marrow and peripheral blood immune cells in a large cohort of patients with smoldering multiple myeloma to examine changes at diagnosis and post-therapy.

Findings presented at the 19th International Myeloma Society Annual Meeting showed that significant changes were detected in the immune-cell composition of patients with smoldering multiple myeloma compared with healthy donors, Sklavenitis-Pistofidis says. Increases were observed in CD4-positive T cells, granzyme B–expressing cytotoxic T cells, and CD56dim natural killer cells. Additionally, decreases were seen in plasmacytoid dendritic cells and CD14-positive monocytes, Sklavenitis-Pistofidis explains.

Notably, patients with immune-cell composition most similar to that of healthy donors had worse outcomes, and patients who were less normal at baseline achieved significantly longer progression-free survival (PFS), Sklavenitis-Pistofidis continues. This condition has been coined immune reactivity, Sklavenitis-Pistofidis adds.

Moreover, a normalization score created by investigators increased on average between baseline and end of treatment throughout 2 years of therapy, Sklavenitis-Pistofidis says. The normalization score can be used to classify patients into those who achieved post-therapy immune normalization and those who did not, Sklavenitis-Pistofidis explains. Patients who achieved post-therapy immune normalization had significantly longer PFS, Sklavenitis-Pistofidis concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD